Latest / Deep Dive Ortho — Orthopaedic Surgery, AI & Digital Health Podcast. / Shoulder Arthritis: Management Across the Life Span

Transcript

Shoulder Arthritis: Management Across the Life Span · Deep Dive Ortho — Orthopaedic Surgery, AI & Digital Health Podcast.

• 0:00
  Welcome to the deep dive. When you think about
• 0:03
  osteoarthritis, well, for most of us, it probably
• 0:07
  brings to mind older people, aching knees perhaps,
• 0:11
  maybe just that unavoidable bit of wear and tear
• 0:15
  that comes with a long life. That's the common
• 0:16
  perception, yes. But the research we're digging
• 0:18
  into today paints a really quite different picture.
• 0:21
  It's frankly quite an urgent story. It is indeed.
• 0:24
  It shows osteoarthritis not just as an older
• 0:27
  person's disease, but something that's actually
• 0:29
  having a significant impact on younger, active
• 0:33
  people. Often triggered by injuries. That's a
• 0:36
  key point. And it comes with a pretty hefty price
• 0:38
  tag, too, doesn't it? Personally, but also economically.
• 0:41
  Absolutely. The costs are substantial. So we've
• 0:43
  gathered research papers looking at, well, everything,
• 0:47
  really, from those subtle early signs. The microscopic
• 0:50
  change is happening inside the joint. right through
• 0:53
  to the sheer numbers who's affected the financial
• 0:55
  fallout. The underlying biology, which is fascinating.
• 0:58
  And of course, what we're actually doing now
• 1:00
  and maybe hoping to do in the future to treat
• 1:02
  it. So our mission in this deep dive is simple,
• 1:06
  really. We want cut through all that complexity,
• 1:09
  pull out the most important insights from these,
• 1:11
  let's face it, quite technical sources. Take
• 1:13
  advance, yes. And give you the clear, actionable
• 1:16
  knowledge you need to get up to speed quickly
• 1:19
  on early OA. You know, what it is, why it's hitting
• 1:23
  younger people, what it really costs, and where
• 1:26
  the science is heading. That's right. And it's
• 1:28
  absolutely crucial, as you said, to understand
• 1:30
  that we're distinguishing early osteoarthritis,
• 1:33
  early OA, as a specific thing. Right. It's not
• 1:36
  just the start of the end -stage disease. Precisely.
• 1:38
  It's not just the very first twinge of late -stage
• 1:41
  disease. Right. Being able to accurately define
• 1:43
  this early phase, both clinically by what we
• 1:46
  see and structurally what's happening at a tissue
• 1:49
  level, That's the real key. Why is that definition
• 1:52
  so important? Because it's how we identify those
• 1:54
  people at highest risk early on. And that's when
• 1:57
  intervention treatment has the greatest potential
• 2:00
  to actually make a difference. The sources we
• 2:02
  looked at highlight that there's been quite significant
• 2:05
  progress recently in refining this definition,
• 2:08
  moving beyond just looking for changes you might
• 2:10
  see on a standard x -ray. Right, looking deeper.
• 2:13
  Let's unpack this insidious phase the papers
• 2:16
  describe. What does that actually mean for someone
• 2:18
  who might be developing early OA? Insidious.
• 2:22
  Well, it basically means it's often subtle. It
• 2:25
  can almost sneak up on you. Not dramatic. Not
• 2:27
  usually, no. Compared to someone with advanced
• 2:30
  OA, who might have constant, quite severe pain,
• 2:34
  patients in this early phase can be largely asymptomatic.
• 2:37
  So feeling nothing at all? Potentially, yes.
• 2:39
  Or they might have symptoms, but they're reduced,
• 2:43
  maybe lower intensity pain, perhaps a bit of
• 2:45
  stiffness, but not necessarily there all the
• 2:48
  time. And the type of pain is different too,
• 2:50
  isn't it? I found the description in the sources
• 2:51
  quite interesting. Yes, it is distinct. In early
• 2:54
  OA, the pain is typically mechanical, so it's
• 2:57
  related to activity. Right. It's often described
• 2:59
  as a sort of deep ache, maybe not always easy
• 3:02
  to pinpoint exactly where it's coming from. Any
• 3:04
  specific activities mentioned? Yes. The sources
• 3:07
  specifically point to weight -bearing activities
• 3:09
  that involve loading and bending the joint. Things
• 3:12
  like using stairs. That's often one of the first
• 3:15
  things people might notice pain with. OK, stairs.
• 3:18
  That's quite specific. And it's a stark contrast
• 3:21
  to advanced OA, where the pain can become constant.
• 3:24
  It might wake people up at night. It's significantly
• 3:27
  worse. with activity, though it might ease off
• 3:30
  a bit with rest. So very different profiles.
• 3:33
  Very different. And there's even uncertainty
• 3:34
  acknowledged in the sources about whether someone
• 3:37
  who feels completely pain -free might actually
• 3:40
  already have underlying early OA changes happening
• 3:42
  silently. That pain -free but changes happening
• 3:44
  idea that really sticks with you, doesn't it?
• 3:47
  It highlights just how subtle this can be. It
• 3:50
  does. So if the clinical signs are minimal, what
• 3:52
  about the physical changes inside the joint?
• 3:55
  Where do they actually start? Well, according
• 3:57
  to these papers, the primary sites of change
• 4:00
  in early OA are the articular cartilage. That's
• 4:03
  the smooth lining on the bone ends. That's the
• 4:06
  one, yes. That smooth surface. And the subconjural
• 4:09
  bone, which is the bone directly underneath the
• 4:11
  cartilage. OK, cartilage and the bone beneath.
• 4:14
  But, and this is important, it's not just those
• 4:15
  two. The sources are very clear. Early OA is
• 4:19
  a whole joint disease. Not just wear and tear
• 4:22
  on one surface, though. Absolutely not. It affects
• 4:24
  all the structures in the joint, the synovial
• 4:26
  membrane, that's the lining, the interpatellar
• 4:29
  fat pad, the menisci, shock absorbers, the joint
• 4:33
  capsule, the ligaments, even the surrounding
• 4:35
  muscles. Changes are happening across the board
• 4:38
  right from the early stages. Wow. OK. So it's
• 4:41
  systemic within the joint. Is there a way researchers
• 4:44
  actually grade these early changes, particularly
• 4:47
  in the cartilage? Yes, there is. The RRSI histopathological
• 4:52
  grading system is key here. It looks at microscopic
• 4:55
  changes in the cartilage tissue itself. Microscopic
• 4:58
  level. Exactly. And the grade is particularly
• 5:00
  relevant for early OA because it reflects the
• 5:03
  depth of the damage. It starts at the surface
• 5:05
  and progresses inwards. So how deep the problem
• 5:08
  goes? Precisely. You might see early disruption
• 5:11
  just on the surface. Maybe tiny cracks. or what
• 5:14
  they call fibrillations. Fibrillations. Like
• 5:17
  tiny fraying. And eventually, you might see vertical
• 5:20
  fissures starting to extend down into the middle
• 5:22
  zone of the cartilage layer. OK. This grating
• 5:25
  focuses on the area with the most advanced damage,
• 5:29
  even if that area is quite small to begin with.
• 5:31
  And you mentioned stage as well. How is that
• 5:34
  different? The stage is about the horizontal
• 5:36
  spread. So how much of the joint surface area
• 5:39
  is affected, grade is depth, stages spread across
• 5:42
  the compartment, and they're considered independent
• 5:44
  of each other. Got it. Clayed for depth, staged
• 5:47
  for spread. And you said the bone underneath
• 5:48
  is changing early too. Correct. The subchondral
• 5:50
  bone shows changes right from the start. There's
• 5:53
  a progressive thickening of the subchondral plate
• 5:56
  that's the very dense layer right under the cartilage,
• 5:59
  and also structural alterations happening, the
• 6:02
  spongiosa, the more porous spongy bone just below
• 6:05
  that. So changes happening at the same time,
• 6:07
  cartilage and bone? Yes, simultaneously. In the
• 6:11
  cartilage layer and the bone supporting it, it's
• 6:13
  a coupled process. Given how subtle the symptoms
• 6:16
  can be and how early these changes start, I'm
• 6:18
  guessing standard imaging like a regular x -ray
• 6:21
  or even a normal MRI isn't brilliant at picking
• 6:24
  this up. That's precisely the challenge. The
• 6:26
  sources explain that conventional morphological
• 6:28
  MRI, which is what's typically used in clinics...
• 6:31
  The standard scan. Yes, the standard scan. It
• 6:34
  often misses these very early changes in the
• 6:37
  cartilage. Things like the initial loss of key
• 6:40
  molecules in the matrix. Like what? Like glycosomic
• 6:43
  glycans or... gags which hold water, and also
• 6:46
  the initial loosening of the collagen network.
• 6:49
  These things can happen when the cartilage still
• 6:51
  looks superficially, pretty normal, or maybe
• 6:54
  only minimally changed on a standard scan. So
• 6:56
  you need something more sophisticated. Absolutely.
• 6:59
  This is where the advanced MRI techniques come
• 7:00
  into play. Methods the source is referred to
• 7:03
  as pre -structural cartilage assessment. Pre
• 7:05
  -structural. So seeing changes before the structure
• 7:07
  visibly breaks down. Exactly. Techniques like
• 7:10
  T2 mapping and DGMR. T2 mapping, for instance,
• 7:14
  can detect subtle changes in the water content
• 7:16
  and the organization of the cartilage matrix
• 7:18
  that signal early degeneration, even before you
• 7:21
  see thinning or defects. That's clever. How does
• 7:24
  it work? Well, T2 values relate to water mobility
• 7:27
  and collagen structure. The sources reference
• 7:29
  data from the big osteoarthritis initiative study.
• 7:32
  The OAI? Yes, the OAI. It showed subtle but significant
• 7:36
  differences in T2 values between healthy knees
• 7:38
  and those with early signs of OA on x -ray. or
• 7:42
  even knees just considered at risk. This suggests
• 7:45
  the technique can pick up early differences that
• 7:47
  might be linked to risk factors. Fascinating.
• 7:49
  Almost like seeing a biochemical footprint the
• 7:51
  standard MRI can't. And what about DGE -ERiC?
• 7:53
  That uses a contrast agent, right? Yes. DGE -ERiC.
• 7:57
  That stands for delayed gadolinium enhanced MRI
• 7:59
  of cartilage. It uses a negatively charged contrast
• 8:02
  agent. Healthy cartilage has lots of negatively
• 8:05
  charged gags which repel the contrast agent.
• 8:08
  Where gags are depleted, in early away, more
• 8:11
  contrast agent can diffuse in. Ah, so less gags
• 8:14
  means more contrast signal. Exactly. By measuring
• 8:17
  how much contrast agent gets into the cartilage
• 8:19
  after a delay, you can indirectly measure the
• 8:22
  JAG concentration. Lower JAGs mean more contrast
• 8:26
  uptake, indicating early degeneration before
• 8:28
  you might see structural loss on a normal scan.
• 8:31
  These advanced techniques are really pushing
• 8:33
  the frontier of detecting the disease much, much
• 8:35
  earlier. It's amazing what they can see now.
• 8:38
  The sources also mention a whole host of different
• 8:39
  scoring systems that researchers use with MRI,
• 8:42
  alongside the older x -ray methods like Kellgren
• 8:45
  -Lawrence that people might be more familiar
• 8:46
  with. Yes, it's a bit of an alphabet soup, isn't
• 8:48
  it? You see Mayoax, Worms, Aqloas, Kimbriss mentioned
• 8:53
  for MRI. Right. And then the familiar Kellgren
• 8:55
  -Lawrence, IKDC, Allbeck scales for x -rays.
• 8:58
  The key point the sources make here is that there's
• 9:01
  actually quite a lot of variation in these different
• 9:04
  assessment tools, especially the semi -quantitative
• 9:06
  MRI ones. Oh, so? Well, they divide the joint
• 9:09
  up differently. They grade features in varying
• 9:11
  ways. This variability isn't just an academic
• 9:14
  detail. It can genuinely affect the outcomes
• 9:16
  reported in different studies. Ah, so it makes
• 9:19
  comparing research harder. Exactly. It makes
• 9:21
  comparing findings across different studies quite
• 9:23
  challenging, especially when you're trying to
• 9:25
  track subtle changes in early disease progression.
• 9:28
  Consistency is key, and we're still working towards
• 9:30
  that. OK, so early OA is subtle, involve specific
• 9:34
  tissue changes in the whole joint, and needs
• 9:37
  advanced tech to really see it early. Now let's
• 9:41
  really focus on who is getting it early. The
• 9:43
  sources make a very strong case for post -traumatic
• 9:46
  osteoarthritis PTOA. They really do. They highlight
• 9:49
  PTOA of the lower extremity, so hip, knee, ankle,
• 9:54
  as a major pathway. They often refer to it using
• 9:57
  phrases like the premature aging of youthful
• 10:00
  joints. Premature aging. That really shifts the
• 10:02
  narrative, doesn't it? It fundamentally changes
• 10:04
  it. It moves away from just thinking about age
• 10:06
  -related wear and tear to a narrative driven
• 10:09
  significantly by joint injury, often happening
• 10:11
  in younger... quite active populations. And the
• 10:14
  statistics provided, particularly around common
• 10:17
  injuries like ACL tears and meniscus tears, they're
• 10:20
  quite stark, actually. They really are. The data
• 10:22
  presented is compelling. If you rupture your
• 10:24
  anterior cruciate ligament, your ACL, or tear
• 10:27
  your meniscus, or maybe even both. Which often
• 10:29
  happens together. Which often happens together,
• 10:31
  yes. You face nearly a 50 % chance of crowing
• 10:35
  flip, basically, of developing symptomatic OA
• 10:37
  within 10 to 20 years of that initial injury.
• 10:41
  50%. Within 10, 20 years, that's huge. It's huge.
• 10:45
  And given that most people who tear their ACL
• 10:47
  are under the age of 30. Right, it's often younger
• 10:49
  athletes. Exactly. This means a significant number
• 10:52
  of people are being diagnosed with PTOA before
• 10:55
  they even turn 50. That's roughly five years
• 10:58
  earlier than the average age of OA onset in the
• 11:01
  general population, which is around 55. So it's
• 11:03
  bringing the onset forward considerably. Considerably.
• 11:06
  The sources mention athletes sometimes showing
• 11:09
  signs as early as their 30s. There's a key study
• 11:12
  by Lomander and colleagues often cited. They
• 11:15
  looked at female soccer players 12 years after
• 11:17
  an ACL reconstruction. They found radiographic
• 11:20
  OA, so visible changes on x -ray in the injured
• 11:23
  knee, in over half of them, 51%. Over half? Compare
• 11:27
  that to their other uninjured knee, only 8 %
• 11:29
  showed OA changes. That difference is massive.
• 11:32
  51 % versus 8%. That's a powerful illustration
• 11:35
  of how much that injury drives the process. Beyond
• 11:38
  that first injury, the sources also talk about
• 11:40
  how common recurrent ACL injury is and the risk
• 11:44
  factors linked to it. Yes, recurrence is a really
• 11:46
  significant concern and unfortunately it happens
• 11:48
  quite frequently. More common than people might
• 11:50
  think. I think so. The sources point to various
• 11:52
  risk factors, but sport type and the level of
• 11:56
  competition really stand out. Higher level, higher
• 11:58
  risk. Seems so. Data from the Moon Group, a large
• 12:01
  U .S. cohort, showed similar risks of re -injuring
• 12:05
  the surgically reconstructed knee and injuring
• 12:07
  the opposite knee within just two years. Another
• 12:10
  study cited looked at NCAA university athletes
• 12:13
  and high school athletes. It found an 8 .7 %
• 12:16
  recurrence rate overall. But the NCAA athletes
• 12:20
  faced a 4 .6 -time higher likelihood of a recurrent
• 12:23
  injury compared to the high schoolers. Four and
• 12:25
  a half times higher at the NCAA level, so the
• 12:28
  intensity and demands of those higher -level
• 12:30
  sports significantly increased the risk of reinjury.
• 12:32
  It appears so. Do they mention which sports had
• 12:35
  the highest rates? Yes. According to a 10 -year
• 12:38
  NCAA study cited, the highest recurrent rupture
• 12:40
  rates when measured per athletic exposure were
• 12:44
  in men's American football, women's gymnastics,
• 12:47
  women's soccer. Okay, interesting mix there.
• 12:50
  They also noted that non -contact recurrent tears,
• 12:53
  so not from a direct hit, were more common in
• 12:55
  the preseason or postseason periods, training
• 12:58
  phases perhaps. Right, maybe when conditioning
• 13:00
  isn't quite optimal. Could be. Interestingly,
• 13:03
  while men overall had a higher rate of recurrent
• 13:05
  rupture in that particular data set, the ratio
• 13:07
  of recurrent injuries compared to primary injuries
• 13:10
  actually decreased for both genders over the
• 13:13
  study period. Oh. What might that suggest? Well,
• 13:17
  it perhaps suggests some improvements over time
• 13:19
  in prevention strategies or maybe surgical techniques
• 13:21
  or rehabilitation. Yeah. Although the absolute
• 13:24
  risk clearly remains significant. So repeated
• 13:26
  injury or maybe just playing certain sports at
• 13:29
  a very high level keeps that OA risk elevated.
• 13:32
  What about meniscus injuries? The sources are
• 13:34
  very direct about that link. One quote says,
• 13:36
  the relationship between meniscal injury and
• 13:38
  OA is plain to see. With considerable literature
• 13:41
  reporting their strong association. Yes, that
• 13:44
  quote really highlights the consensus in the
• 13:46
  field. A meniscal injury immediately fundamentally
• 13:50
  alters the joint environment. How so? The sources
• 13:54
  explain that the OA cycle begins very early after
• 13:56
  injury, often at a cellular and biochemical level.
• 14:00
  even before the mechanical changes become really
• 14:02
  obvious. So change is happening unseen. Exactly.
• 14:05
  When the meniscus is damaged, it loses its ability
• 14:08
  to perform its vital functions, distributing
• 14:10
  load evenly across the joint, absorbing shock,
• 14:13
  providing stability. And this mechanical failure
• 14:16
  essentially accelerates the breakdown process
• 14:18
  that leads to OA. The greater the initial damage
• 14:21
  to the meniscus, the more impaired its biomechanical
• 14:23
  function becomes, and generally, the faster the
• 14:26
  OA progression. Are certain types of meniscus
• 14:29
  tears worse than others for triggering OA? Yes,
• 14:32
  the research points quite strongly in that direction.
• 14:34
  The sources specifically call out meniscal extrusions.
• 14:37
  Extrusions? What's that? That's where the meniscus
• 14:40
  sort of gets squeezed out from its normal position
• 14:42
  between the bones. That... and large radial tears
• 14:46
  that run across the width of the meniscus. Right.
• 14:48
  These seem to be the most significant contributors
• 14:50
  to the onset and progression of OA. More so than
• 14:53
  other tear types. They note that smaller tears,
• 14:56
  perhaps like longitudinal tears running along
• 14:58
  the length of the meniscus, might have less dramatic
• 15:01
  initial biochemical effects, which perhaps means
• 15:04
  their long -term OA risk might sometimes be underestimated.
• 15:08
  Okay. And what about surgery? Specifically, removing
• 15:11
  torn meniscal tissue A meniscectomy. How does
• 15:15
  that impact the joint long -term? Ah, well, the
• 15:18
  sources are pretty clear on this. Meniscectomy,
• 15:20
  especially removing a significant portion, significantly
• 15:23
  accelerates degenerative changes in the joint.
• 15:26
  Even if it helps symptoms initially? Yes, that's
• 15:28
  the paradox. Studies with long -term follow -up
• 15:31
  show clear radiological progression of OA after
• 15:34
  meniscectomy, even if patients report feeling
• 15:36
  much better clinically in the short term. Any
• 15:38
  specific studies mentioned? The Paradoski study
• 15:41
  is cited as a prime example. It followed patients
• 15:44
  for nearly 25 years after meniscectomy. 25 years.
• 15:48
  Yes, a long time. It showed a much higher incidence
• 15:52
  of OA both in the main tibiofemoral joint and
• 15:56
  behind the kneecap, the patellofemoral joint,
• 15:59
  as well as other structural changes in the operated
• 16:01
  knee compared to the unoperated knee. That's
• 16:04
  compelling long -term evidence. It is. And a
• 16:07
  more recent study also found significant OA progression
• 16:10
  after arthroscopic partial menesectomy, just
• 16:13
  removing the torn part, particularly noting higher
• 16:16
  risk in patients with a higher BMI and those
• 16:19
  with degenerative tears rather than acute traumatic
• 16:22
  tears. They point out this finding actually goes
• 16:24
  against some of the previous literature, which
• 16:26
  sometimes suggested degenerative tears were less
• 16:28
  problematic. So it seems even partial removal
• 16:31
  carries a significant long -term risk. It sounds
• 16:33
  like while menesectomy might fix immediate symptoms,
• 16:35
  your potential borrowing from the future health
• 16:37
  of the joint. That's a very good way to put it.
• 16:39
  It's the difficult trade -off that's highlighted.
• 16:42
  The sources strongly conclude that patients with
• 16:44
  any significant meniscal injury should be considered
• 16:47
  at high risk for developing OA down the line.
• 16:49
  So what's the implication for treatment then?
• 16:52
  It emphasizes the need for treatments that are
• 16:54
  really focused on restoring the meniscus' integrity
• 16:57
  and function whenever possible. So repair rather
• 17:00
  than removal if feasible. But they also know
• 17:03
  that even surgical treatments, whether it's a
• 17:06
  repair or a partial removal, still carry an increased
• 17:09
  OA risk compared to a completely healthy joint.
• 17:12
  So no easy answers. No easy answers. Deciding
• 17:15
  how to manage a tear requires very careful consideration
• 17:18
  of the individual patient, their activity level,
• 17:21
  their age, and the specific characteristics of
• 17:23
  their tear. Beyond the ACL and menistis, the
• 17:25
  sources briefly mention intraarticular fractures
• 17:27
  breaks that go right into the joint surface as
• 17:30
  another cause of PTOA. Yes, IAFs are acknowledged
• 17:33
  as contributing to the risk of developing PTOA.
• 17:36
  The sources state that while this link is known,
• 17:39
  we actually need more research to better quantify
• 17:41
  the risk associated with different fracture types
• 17:44
  and patterns. And to develop better treatments.
• 17:46
  Exactly. To develop and implement treatments
• 17:48
  that can truly mitigate that risk and prevent
• 17:51
  or delay PTOA in these often complex injury cases.
• 17:55
  Okay. So we've firmly established that injuries
• 17:58
  are a major driver of early OA, particularly
• 18:01
  in younger active people. Why is this becoming
• 18:05
  such a significant problem, especially from an
• 18:08
  economic perspective, hitting people who are
• 18:10
  often in their working prime? This is where the
• 18:13
  picture really broadens out beyond just personal
• 18:15
  health to become a major societal and economic
• 18:17
  challenge. Unlike many older OA patients who
• 18:20
  might already be retired, these younger individuals
• 18:23
  are typically right in the middle of their working
• 18:24
  lives, often with decades of career ahead of
• 18:27
  them. So the impact isn't just the direct medical
• 18:29
  cost. It's about lost productivity, isn't it?
• 18:32
  Exactly that. When a younger adult develops debilitating
• 18:35
  pain and the limited mobility that can come with
• 18:38
  OA, it severely impacts their ability to work
• 18:40
  effectively. or sometimes to work at all. Leading
• 18:43
  to time off or even leaving work altogether?
• 18:46
  Yes, it significantly increases their risk of
• 18:48
  having to withdraw from the workforce early.
• 18:51
  The sources cite a really striking statistic.
• 18:54
  What's that? That arthritis... and OA is the
• 18:56
  most common form, increases a person's risk of
• 18:59
  being out of the labor force entirely by a staggering
• 19:02
  64%. 64%. That's a massive potential impact on
• 19:06
  someone's career path and financial stability.
• 19:08
  It's huge. And the sheer number of lost work
• 19:10
  days nationally, it's immense. How immense. The
• 19:13
  United States Bone and Joint Initiatives 2016
• 19:16
  report found that adults with osteoarthritis
• 19:18
  reported something like 180 .9 million total
• 19:21
  lost work days just between 2013 and 2014. And
• 19:26
  to put that to sharp relief, that figure represented
• 19:28
  34 % over a third of all lost work days reported
• 19:31
  for any medical condition during that period.
• 19:33
  A third of all lost work days across all conditions,
• 19:36
  just from OA. That statistic alone should make
• 19:40
  employers, policymakers, everyone really pay
• 19:42
  attention. It's a staggering figure. It highlights
• 19:45
  that OA is a leading cause of lost work time
• 19:47
  and productivity. Full stop. And the direct medical
• 19:50
  costs involved? Are they higher for younger patients,
• 19:53
  too? They were, according to the McLean and Adelol
• 19:55
  data cited in the sources. Even back in the early
• 19:58
  90s, they showed higher direct medical costs
• 20:01
  per year for patients under 65, around $2 ,800,
• 20:06
  than compared to those over 65 who are closer
• 20:08
  to $2 ,000 per year. Why would that be? Well,
• 20:11
  the reason this translates into what the source
• 20:13
  has called hefty cumulative costs over a lifetime
• 20:15
  is simply because these younger patients live
• 20:18
  with the disease for so much longer. Ah, right.
• 20:21
  years of needing treatment. Exactly. An older
• 20:23
  patient might develop OA and live with it for,
• 20:25
  say, 10 or 15 years. A younger patient diagnosed
• 20:28
  in their 30s or 40s could have it for 30, 40,
• 20:30
  even 50 years, accumulating medical expenses,
• 20:34
  needing potentially multiple interventions over
• 20:36
  that entire extended period. So for our listeners,
• 20:38
  many of whom are professionals navigating their
• 20:40
  own careers, this isn't just about potentially
• 20:42
  managing a future health issue for themselves
• 20:45
  maybe decades down the line. No, not at all.
• 20:47
  It's about understanding a force that significantly
• 20:50
  impacts workforce productivity right now, affects
• 20:53
  career longevity, and has major implications
• 20:56
  for long -term financial well -being, both for
• 20:59
  individuals and for the organizations they work
• 21:01
  for. That's a critical point to grasp. The economic
• 21:05
  burden of early OA and younger working -age individuals
• 21:09
  is a major concern that affects employers healthcare
• 21:12
  systems, and national economies, not just the
• 21:15
  person with the sore joint. Understanding this
• 21:17
  broader impact is vital for informed planning
• 21:19
  and resource allocation. OK, we've covered the
• 21:22
  subtle symptoms, the strong link to injury in
• 21:24
  younger people, and this huge economic cost.
• 21:28
  Now, let's really get into the science behind
• 21:30
  it. The sources fundamentally challenge that
• 21:32
  old idea of OA being just simple wear and tear,
• 21:35
  don't they? They position it much more as an
• 21:37
  inflammatory process. Yes. This shift in understanding
• 21:40
  has been a really big development, gathering
• 21:42
  pace since the 1990s, largely driven by advances
• 21:45
  in molecular biology. The old purely mechanical
• 21:48
  view is just too simplistic. So inflammation
• 21:51
  isn't just a side effect? No. The evidence presented
• 21:54
  here from multiple studies strongly points to
• 21:57
  inflammation within the joint, specifically inflammation
• 21:59
  of the synovial lining, synovitis, as a crucial
• 22:02
  feature of early OA pathology. It's not just
• 22:05
  something that happens late in the game. It seems
• 22:07
  to be part of the core disease process right
• 22:09
  from the beginning, especially after injury.
• 22:12
  How does this inflammatory process actually work
• 22:14
  then? How does it break down the joint? Well,
• 22:17
  it involves a pretty complex chain reaction.
• 22:20
  Damage or injury triggers the release of molecules
• 22:22
  within the joint that shouldn't normally be floating
• 22:25
  around freely. Bits of Damage Matrix, for example.
• 22:28
  Danger signals. Exactly. They act as danger signals,
• 22:30
  or what scientists call alarmans. These activate
• 22:33
  the innate immune system cells that reside within
• 22:36
  the joint tissues. This activation leads to a
• 22:38
  cascade involving the production of inflammatory
• 22:40
  mediators and destructive enzymes. Key players
• 22:44
  include enzymes that degrade the extracellular
• 22:46
  matrix. the stuff that holds cartilage together.
• 22:49
  Things like MMPs, matrix metalloproteinases,
• 22:53
  and NMMTS enzymes. They chew up the cartilage.
• 22:56
  Essentially, yes. They break down important components
• 22:58
  like agrikin and collagen. At the same time,
• 23:01
  the cartilage cells themselves, the chondroides,
• 23:04
  get switched into a catabolic state. Meaning?
• 23:07
  Meaning they start producing more of these breakdown
• 23:09
  enzymes and fewer of the molecules needed to
• 23:11
  maintain the tissue. They shift from building
• 23:14
  and maintaining to breaking down. This is driven
• 23:16
  by factors like inflammatory cytokines, signaling
• 23:19
  molecules like interleukin -1 and TNF -alpha,
• 23:22
  and prostaglandins, which are released in that
• 23:24
  inflammatory environment. And the source has
• 23:26
  mentioned specific molecular pathways being switched
• 23:29
  on, like NFKB. Yes. The activation of transcription
• 23:32
  factors like NFKB is seen as a central event
• 23:34
  in this process. When NFKB gets activated in
• 23:37
  cells within the cartilage, the bone, and the
• 23:39
  synovium, it essentially tells those cells to
• 23:41
  ramp up production of a whole host of inflammatory
• 23:44
  mediators, TNF alpha, IL -1 beta, IL -6, and
• 23:48
  others. Creating a hostile environment. Precisely.
• 23:51
  It creates this hostile inflammatory environment
• 23:53
  within the joint that accelerates tissue damage.
• 23:56
  It also leads to the excessive generation of
• 23:58
  reactive oxygen species, ROS. Free radicals.
• 24:01
  Think of them like damaging free radicals, yes.
• 24:04
  This causes oxidative stress, further tissue
• 24:06
  damage, and contributes to a kind of accelerated
• 24:09
  cellular aging or senescence within the joint
• 24:12
  tissues. It sounds like a vicious cycle. It really
• 24:15
  is often described as a feed -forward catabolic
• 24:17
  cycle. It involves all the joint tissues feeding
• 24:19
  into each other's dysfunction. And the evidence
• 24:22
  for this is overwhelming. You find elevated levels
• 24:25
  of these inflammatory markers in OA joint tissues
• 24:27
  and in the synovial fluid and synovitis that
• 24:30
  inflammation of the joint lining is consistently
• 24:33
  present even in the early stages of the disease.
• 24:36
  So it's a destructive cycle really powered by
• 24:38
  inflammation. Are there particular inflammatory
• 24:41
  signals or specific immune cells that seem especially
• 24:43
  important in early OA? Perhaps areas where intervention
• 24:47
  might be possible to break that cycle. Yes, interleukin
• 24:50
  -1 or IL -1 is definitely highlighted in the
• 24:52
  sources. They note that, particularly after an
• 24:55
  injury, there seem to be relatively unopposed
• 24:58
  increases in IL -1 activity within the joint.
• 25:01
  And IL -1 is bad for cartilage? It's strongly
• 25:04
  catabolic, yes. It drives cartilage breakdown.
• 25:06
  And levels of its natural inhibitor, IL -1 receptor
• 25:09
  antagonist, or IL -1RO, seem to decrease as cartilage
• 25:13
  damage gets worse. Laboratory studies also show
• 25:15
  that the superficial layers of cartilage are
• 25:17
  particularly vulnerable to damage induced by
• 25:19
  IL -1. Does this biochemical finding link back
• 25:22
  directly to how patients actually do, to the
• 25:25
  outcomes we talked about earlier? Yes. There's
• 25:27
  compelling evidence suggesting it does. The sources
• 25:30
  cite studies showing a direct correlation. Levels
• 25:32
  of inflammatory cytokines like IL -1 -alpha and
• 25:35
  cartilage degrading enzymes like MMP9 measured
• 25:38
  in the joint fluid on the very day someone has
• 25:40
  ACL reconstruction surgery. Right after the injury
• 25:43
  and surgery. Exactly. Those levels actually correlate
• 25:46
  with the amount of cartilage change seen on MRI
• 25:49
  scans three years later. Wow. And perhaps more
• 25:52
  importantly, higher levels of these inflammatory
• 25:55
  markers measured at the time of surgery were
• 25:58
  associated with worse patient -reported outcomes
• 26:00
  down the line. Things like lower quality of life
• 26:03
  scores, more pain, poorer function. That's powerful.
• 26:07
  It suggests the inflammatory environment present
• 26:09
  right from the start isn't just a temporary blip.
• 26:12
  It seems to set the stage for long -term problems.
• 26:14
  It really does. It indicates that this early
• 26:17
  heightened inflammation can lead to issues like
• 26:19
  recurrent joint swelling, persistent synovitis,
• 26:22
  and ultimately continued cartilage breakdown
• 26:24
  with long -term consequences. The sources also
• 26:27
  discuss the role of specific immune cells, don't
• 26:29
  they? Particularly T cells and macrophages. Yes,
• 26:32
  the chapter focusing on T cells makes point of
• 26:34
  stating its focus is on their role in early OA.
• 26:37
  Why? Because that's really the window of opportunity
• 26:39
  where we might actually be able to intervene
• 26:42
  effectively to prevent or truly modify the long
• 26:46
  -term disease course rather than just managing
• 26:48
  late -stage symptoms. Makes sense. How are T
• 26:52
  cells involved? Well, damaged joint cells release
• 26:54
  chemical signals. chemokines that act like beacons,
• 26:57
  attracting T cells from the bloodstream into
• 26:59
  the inflamed joint. Different types or subtypes
• 27:02
  of T cells seem to be involved. Different jobs.
• 27:05
  Broadly, yes. And the specific mix of cytokines
• 27:08
  already present in the joint environment influences
• 27:11
  which T cell types are recruited and what they
• 27:13
  subsequently do. Some might promote further inflammation,
• 27:16
  while others could potentially help to resolve
• 27:18
  it. Which subtexts are mentioned? The sources
• 27:19
  mention the general subtypes people might have
• 27:22
  heard of Th1, Th2, Th17, and TREGs and their
• 27:26
  broad functions. Th1 cells, for example, often
• 27:28
  associated with activating phagocytic cells,
• 27:31
  Th2 with responses to parasites, Th17 with bacterial
• 27:35
  defense, and TREGs are generally immunosuppressive.
• 27:38
  But it's complicated in no way. Very. The sources
• 27:41
  stress that the exact interplay between these
• 27:44
  different T -cell subsets within the OA -joint
• 27:46
  environment is still being unraveled and needs
• 27:48
  much more research, understanding that interplay
• 27:51
  is crucial if we want to develop targeted immunotherapies
• 27:54
  that could work early in the disease process.
• 27:56
  OK, so T -cells are players, but the details
• 27:58
  are still being worked out. What about macrophages?
• 28:01
  They're major immune cells too. Macrophages are
• 28:03
  definitely key players. They are known producers
• 28:06
  of inflammatory mediators like TNF -alpha. One
• 28:09
  animal model study mentioned showed that after
• 28:11
  an ACL injury, there were increased levels of
• 28:13
  a molecule called macrophage in inflammatory
• 28:15
  protein 1 gamma, in the joint lining, the synovium.
• 28:19
  MIP1 gamma. What does that do? Well, it acts
• 28:22
  as a potent chemoattractant, recruiting other
• 28:25
  inflammatory cells to the site. But interestingly,
• 28:27
  it also influences bone resorption by regulating
• 28:29
  osteoclasts, the cells that break down bone.
• 28:32
  Ah, so linking inflammation and bone changes?
• 28:35
  Potentially, yes. A study cited demonstrated
• 28:37
  that a specific type of T cell, the CD4 plus
• 28:40
  T helper cells, seemed to influence OA progression,
• 28:44
  partly by regulating this MIP1 production. How
• 28:47
  did they show that? In a mouse model, silencing
• 28:51
  the gene for MIP1 actually reduced the infiltration
• 28:55
  of immune cells and macrophages into the joint
• 28:57
  after injury. It also lowered inflammation markers
• 29:00
  like IL -1 expression, decreased the number of
• 29:03
  bone -resorbing osteoclasts, and ultimately reduced
• 29:06
  the amount of cartilage damage. Targeting MIP1
• 29:09
  could potentially interrupt both the inflammatory
• 29:12
  cascade and the associated bone changes. That
• 29:14
  sounds promising. It suggests it could be a potential
• 29:17
  therapeutic target, yes. Yeah. Though, obviously,
• 29:20
  translating that from mice to humans is a big
• 29:22
  step. Of course. It's clear the biology is incredibly
• 29:24
  complex and highly inflammatory. But can we really
• 29:28
  separate that entirely from mechanics? How does
• 29:30
  mechanical load, the forces going through the
• 29:32
  joint, fit into this inflammatory picture? This
• 29:34
  is a really critical intersection that the sources
• 29:37
  explore in detail. And it has huge implications
• 29:40
  for things like rehabilitation and advising people
• 29:42
  on activity levels. How so? Well, firstly, they
• 29:44
  cite studies showing that very high intensity,
• 29:47
  sudden impact loading like a jump landing, perhaps
• 29:49
  can actually cause chondrocyte death directly.
• 29:52
  Just kill the cartilage cells. Yes, through a
• 29:55
  specific cellular pathway involving the mitochondria,
• 29:59
  the cell's powerhouses, and the production of
• 30:01
  those reactive oxygen species, ROS we mentioned
• 30:04
  earlier. It suggests that sheer force can trigger
• 30:07
  a kind of biologically programmed cell death.
• 30:10
  It's not just physically squashing them. That's
• 30:13
  a direct biological link between excessive force
• 30:15
  and cell death. Is it preventable? Intriguingly,
• 30:19
  in laboratory settings, yes, disrupting this
• 30:21
  specific pathway, for example using a simple
• 30:24
  antioxidant compound, markedly decreased the
• 30:27
  ROS levels and the amount of cell death observed
• 30:29
  after impact loading. This points towards potential
• 30:32
  protective strategies, although applying that
• 30:34
  in vivo in a person is another matter. Still,
• 30:37
  fascinating. What else about mechanics? The sources
• 30:39
  also note that after an injury like an ACL tear,
• 30:42
  people often develop altered movement patterns.
• 30:44
  They might subconsciously avoid loading the injured
• 30:47
  leg, leading to underloading. Or they might compensate
• 30:50
  in ways that actually overload other parts of
• 30:52
  the same joint, or the other leg, during activities
• 30:55
  like walking, running, or squatting. And these
• 30:58
  abnormal loading patterns are strongly linked
• 31:00
  to subsequent degeneration in both the cartilage
• 31:03
  and the underlying bone. So altered mechanics
• 31:05
  drive degeneration? Yes. And furthermore, even
• 31:09
  in what we call idiopathic OA, the type not directly
• 31:12
  linked to a major injury altered mechanics resulting
• 31:15
  from previous Maybe minor injuries or alignment
• 31:18
  issues can accelerate the disease process. And
• 31:21
  this brings us back to that really crucial finding
• 31:23
  you mentioned earlier about the difference between
• 31:25
  high impact versus low impact loading and inflammation.
• 31:29
  Yes, this is foundational for thinking about
• 31:31
  activity. The research suggests that high impact
• 31:34
  loading seems to have the potential to actually
• 31:36
  increase pro -inflammatory activity within the
• 31:38
  joint, specifically by activating that NFKB pathway
• 31:42
  we discussed. So heavy impact can ramp up inflammation?
• 31:45
  It appears so. Conversely, lower intensity loading,
• 31:48
  more gentle, controlled movement appears to decrease
• 31:50
  this inflammatory activity. That's a critical
• 31:52
  distinction. It really is. This isn't just about
• 31:55
  avoiding physical damage to the tissue. It's
• 31:57
  about how mechanical forces directly influence
• 32:00
  the biological environment and the inflammatory
• 32:03
  signaling within the joint. This has profound
• 32:06
  implications for how we design rehabilitation
• 32:08
  programs after injury and how we advise patients
• 32:11
  on returning to activity. It strongly suggests
• 32:14
  that the quality and intensity of the load placed
• 32:17
  on the joint matter significantly for its long
• 32:19
  -term biological health, not just as mechanical
• 32:22
  integrity. That connection between specific mechanical
• 32:25
  loads and the underlying inflammatory pathways
• 32:29
  That feels like a major takeaway. It suggests
• 32:31
  rehab isn't just about restoring strength and
• 32:33
  movement. It's potentially about actively managing
• 32:36
  the biological environment through movement.
• 32:38
  Precisely. It opens up a whole new dimension
• 32:40
  to therapeutic exercise. Okay, let's shift gears
• 32:42
  now and talk about treatment strategies. Given
• 32:45
  this complex, evolving understanding of early
• 32:48
  OA, the inflammation, the mechanics, the injury
• 32:50
  link, what approaches are currently being used,
• 32:53
  or perhaps being explored for the future, the
• 32:55
  sources cover a pretty wide range. Starting logically
• 32:58
  with non -surgical options, which are often focused
• 33:01
  on managing symptoms initially. Pain management
• 33:04
  is obviously primary. What are the main options
• 33:06
  there? Well, simple analgesics like acetaminophen,
• 33:09
  paracetamol are noted as having a good safety
• 33:12
  profile, especially for older adults or those
• 33:15
  with stomach issues, but they lack a direct anti
• 33:18
  -inflammatory effect. Compared to NSAIDs? Compared
• 33:20
  to non -steroidal anti -inflammatory drugs, NSAIDs,
• 33:23
  yes. NSAIDs can reduce inflammation as well as
• 33:26
  pain. which might be advantageous, but they carry
• 33:29
  other risks, like gastrointestinal or cardiovascular
• 33:32
  side effects, particularly with long -term use.
• 33:34
  What about supplements do they get a mention?
• 33:36
  Oral vitamins, specifically vitamin C and D,
• 33:39
  are mentioned. This is partly based on NICE UK
• 33:42
  guidelines, which include them as an optional
• 33:44
  part of managing shoulder problems. But the sources
• 33:47
  discuss their potential relevance more broadly.
• 33:49
  How might they help? Vitamin C is highlighted
• 33:51
  for potential chondroprotective effects. It's
• 33:54
  an antioxidant, It might help reduce programmed
• 33:56
  cell death, apoptosis, in cartilage cells. And
• 33:59
  some studies suggest it can stimulate the production
• 34:01
  of key cartilage matrix components like agrikin
• 34:04
  and type 2 collagen. So potentially boosting
• 34:07
  the cartilage's own repair capacity? That's the
• 34:10
  theory. A study by Wang from 2004 is cited which
• 34:13
  linked higher vitamin C intake to a three -fold
• 34:16
  decrease in OA incidence and also pain reduction
• 34:19
  in people with hip or knee OA. The sources suggest
• 34:22
  these findings might be relevant even if direct
• 34:25
  evidence specifically for the shoulder, for instance,
• 34:27
  is less robust. Vitamin D is also important for
• 34:30
  bone health generally, which is relevant given
• 34:32
  the subconjural bone changes in OA. Okay. And
• 34:35
  rehabilitation. That must be central, especially
• 34:36
  after an injury or surgery. Absolutely vital.
• 34:39
  Using the example of post -shoulder surgery recovery,
• 34:42
  a structured progressive rehabilitation program
• 34:44
  is essential. What are the goals? Initially,
• 34:47
  to regain range of motion safely and prevent
• 34:49
  stiffness or scarring. Then, to progressively
• 34:52
  strengthen the key stabilizing muscles, like
• 34:55
  the rotator cuff and the muscles around the shoulder
• 34:58
  blade. And finally, a gradual controlled return
• 35:02
  to normal activities and potentially sport. Full
• 35:05
  recovery often takes a significant amount of
• 35:07
  time, maybe four to six months. or even longer.
• 35:10
  There's also that ongoing debate, particularly
• 35:12
  after injuries like ACL tears, about conservative
• 35:15
  management rehab alone versus surgical reconstruction.
• 35:19
  Do those sources touch on the cost effectiveness
• 35:21
  aspect of that? Yes, they do. Studies have tried
• 35:23
  to crunch the numbers on this. Some analyses,
• 35:26
  like one by Mather and colleagues cited, which
• 35:28
  use data from large cohort studies like Moon
• 35:31
  and Kana. Okay. They found that ACL reconstruction
• 35:33
  appeared to be more cost -effective than rehabilitation
• 35:36
  alone when measured in terms of gaining quality
• 35:38
  -adjusted life years, or QALYs. They even suggested
• 35:42
  it might offer overall cost savings in the long
• 35:44
  term. Another study by Lubowitz also supported
• 35:47
  the cost -effectiveness of reconstruction based
• 35:49
  on QAL gains. But it's not unanimous. Not entirely.
• 35:53
  A Swedish study mentioned found that while conservative
• 35:56
  management had lower initial costs, it also resulted
• 35:59
  in lower QALY gains, particularly when QALYs
• 36:03
  were calculated based on activity level achieved.
• 36:07
  So how you measure the outcome can influence
• 36:09
  the conclusion. They also mentioned specific
• 36:12
  cost -effectiveness analyses looking just at
• 36:15
  competitive athletes, where the demands are obviously
• 36:17
  higher. And this links right back to our earlier
• 36:19
  point about mechanical loading influencing inflammation,
• 36:22
  doesn't it? The sources emphasize that guidelines
• 36:25
  for returning to physical activity need to consider
• 36:27
  more than just strength or stability. Exactly.
• 36:30
  They need to consider how different activities
• 36:32
  and the specific loads they involve might be
• 36:35
  influencing that underlying inflammatory process
• 36:37
  and the health of the cartilage over the long
• 36:39
  term. It's not just about whether you can physically
• 36:41
  do an activity, but what impact that activity
• 36:44
  is having inside the joint at a biological level.
• 36:47
  High impact might feel okay initially, but could
• 36:49
  potentially be driving low -grade inflammation,
• 36:52
  whereas lower -intensity loading might actually
• 36:53
  be beneficial for joint homeostasis. A really
• 36:56
  important consideration for long -term joint
• 36:58
  health. Moving on to injection therapies. These
• 37:01
  are less invasive than surgery and seem to be
• 37:04
  very widely used for symptom control. Yes, they
• 37:07
  play a major role in OA management. Corticosteroid
• 37:10
  injection steroid jabs are very common for managing
• 37:13
  pain and symptom flare -ups. The sources note
• 37:16
  that using imaging guidance, like ultrasound,
• 37:18
  to ensure accurate placement improves the results.
• 37:21
  But there are downsides. Yes, a significant caveat
• 37:24
  is mentioned repeatedly. The potential for corticosteroids,
• 37:27
  especially with the repeated injections, to have
• 37:29
  harmful or deleterious effects on the cartilage
• 37:32
  itself. This is a particular concern in younger,
• 37:35
  more active patients where preserving cartilage
• 37:37
  health long term is paramount. Okay. What about
• 37:40
  hyaluronic acid injections, VSCO supplementation?
• 37:43
  Hyaluronic acid or HA, is a natural component
• 37:46
  of the synovial fluid in our joints. It provides
• 37:49
  lubrication, and shock absorption gives the fluid
• 37:51
  its viscosity. And that's reduced in OA. Yes.
• 37:54
  In OA, the concentration and the quality, the
• 37:58
  molecular weight, of HA in the joint fluid are
• 38:00
  reduced. So these injections aim to supplement
• 38:04
  that, to restore some of that lubrication, and
• 38:07
  potentially have some mild anti -inflammatory
• 38:09
  or pain -relieving effects. It's primarily seen
• 38:12
  as a symptomatic treatment, though. And platelet
• 38:15
  -rich plasma, PRP, that seems to be increasingly
• 38:17
  popular. PRP is another option. It involves taking
• 38:21
  a sample of the patient's own blood, spinning
• 38:23
  it down to concentrate the platelets, and then
• 38:25
  injecting that platelet -rich plasma back into
• 38:28
  the joint. What's the thinking behind that? Platelets
• 38:30
  are packed with growth factors and other signaling
• 38:32
  molecules. When injected into the joint, they
• 38:35
  release these factors, which are thought to influence
• 38:38
  the joint environment, potentially reducing inflammation,
• 38:41
  promoting some healing responses, improving symptoms
• 38:44
  and function. Does it work? The sources suggest
• 38:46
  PRP can have positive effects on joint homeostasis,
• 38:50
  reducing symptoms, improving function, and perhaps
• 38:53
  delaying the need for surgery in some patients.
• 38:56
  There's a note that it seems to work better in
• 38:58
  joints with earlier stages of degeneration rather
• 39:01
  than advanced OA. A meta -analysis is cited evaluating
• 39:04
  its effectiveness, particularly for knee cartilage
• 39:07
  problems and OA. Okay, so those are mainly managing
• 39:10
  symptoms, but there's huge interest now in approaches
• 39:13
  that might actually regenerate tissue or fundamentally
• 39:15
  change the disease process. biologics, like cell
• 39:19
  -based therapies. The sources delve quite deeply
• 39:22
  into mesenchymal stromal cells, or MSCs. Yes.
• 39:25
  MSCs, sometimes called mesenchymal stem cells,
• 39:28
  are a major focus of regenerative medicine research
• 39:30
  for OA. These are cells that can be isolated
• 39:33
  from various tissues in the body. Where do they
• 39:34
  come from? Lots of places. Bone marrow is a common
• 39:37
  source. Also adipose tissue, fat, the synovial
• 39:40
  membrane lining the joint itself, even umbilical
• 39:42
  cord tissue, dental pulp. The list is quite long.
• 39:45
  Are they all the same? And that's a critical
• 39:47
  point the sources make right away. MSCs derived
• 39:50
  from these different tissues are not equivalent.
• 39:52
  They have variations in their properties, their
• 39:54
  surface markers, their differentiation potential.
• 39:57
  This inherent variability makes comparing results
• 40:00
  from studies using MSCs from different sources
• 40:02
  quite complicated. Right. How are MSCs actually
• 40:05
  thought to help in an osteoarthritic joint? Well,
• 40:09
  there are potentially a couple of main mechanisms.
• 40:12
  One is their potential to differentiate, to turn
• 40:14
  into other cell types, like chondrocytes, cartilage
• 40:17
  cells, or osteoblasts, bone -forming cells. So
• 40:22
  theoretically, they could help rebuild damaged
• 40:24
  tissue directly. But is that the main way? Increasingly,
• 40:26
  the evidence points towards their paracrine effects
• 40:29
  being the dominant mechanism. Paracry. Meaning
• 40:31
  they work by signaling to other cells. MSCs release
• 40:35
  a whole cocktail of bioactive molecules, growth
• 40:37
  factors, cytokines, and importantly, extracellular
• 40:40
  vesicles, including exosomes. Exosomes. Tiny
• 40:42
  packages. Exactly. Tiny membrane -bound packages
• 40:45
  containing proteins, RNA, lipids. These secreted
• 40:49
  factors are thought to have powerful effects
• 40:50
  on the surrounding joint tissues, calming inflammation,
• 40:53
  immunomodulation, promoting tissue regeneration,
• 40:56
  reducing pain. analgesic effects. It's this communication
• 40:59
  with the existing joint cells that seems key.
• 41:02
  Have clinical trials actually shown that injecting
• 41:04
  MSCs can regenerate cartilage in OA patients?
• 41:08
  Clinical trials using intraarticular meaning
• 41:10
  injected into the joint MSCs are still relatively
• 41:12
  limited in number and scale. And the evidence
• 41:14
  for true robust articular cartilage regeneration
• 41:17
  that you can clearly see on an MRI scan has been
• 41:20
  variable. It's not consistently demonstrated
• 41:22
  yet. But any promising signs? Yes. One study
• 41:25
  specifically cited in the sources did report
• 41:27
  not only improved function and reduced pain,
• 41:29
  but also reduced cartilage defect size and, encouragingly,
• 41:32
  evidence of hyaline -like cartilage regeneration
• 41:35
  on MRI after injecting adipose -derived MSCs
• 41:38
  into osteoarthritic knees. So it is possible,
• 41:41
  but maybe not guaranteed. Are there ways to enhance
• 41:43
  their effect? The idea of combining MSCs with
• 41:46
  other things like supportive biomaterials or
• 41:49
  carriers, perhaps PRP, fibrin gel, or hyaluronic
• 41:52
  acid is being actively explored. The hope is
• 41:56
  that these might help the MSCs stay in the joint
• 41:58
  longer, survive better, and potentially promote
• 42:01
  their matrix -producing activity, enhancing the
• 42:04
  therapeutic benefit. What about practical things
• 42:06
  like how many cells to use or when to inject
• 42:08
  them? That's still largely unknown. Dose -response
• 42:11
  relationships have been observed in some studies
• 42:13
  suggesting more cells might be better up to a
• 42:16
  point by the optimal cell number, the best timing
• 42:18
  for injection, how soon after injury or at what
• 42:21
  stage of OA, and how often injections might be
• 42:23
  needed. These are all significant unanswered
• 42:26
  questions. But is there any consensus on timing?
• 42:28
  A key takeaway from the sources is that MSC therapy
• 42:31
  is likely to be most beneficial when applied
• 42:33
  as early as possible after a joint injury or
• 42:36
  in the early stages of OA development. Why early?
• 42:39
  The rationale is to intervene before extensive
• 42:41
  irreversible damage has occurred. The idea is
• 42:45
  to use the MSC's immunomodulatory and regenerative
• 42:48
  signaling effects to help restore joint homeostasis,
• 42:52
  calm that early inflammation, and protect the
• 42:54
  remaining cartilage from further degradation.
• 42:57
  Any evidence for that early intervention idea?
• 42:59
  A pre -clinical study in a large animal model
• 43:02
  relevant because their joints are more similar
• 43:04
  to humans, supported this. They injected specifically
• 43:07
  selected adipose -derived MSCs into the joint
• 43:11
  just four days after surgically inducing an injury.
• 43:13
  And the result? It prevented the progression
• 43:15
  of early post -traumatic OA changes, it reduced
• 43:18
  cartilage degeneration, and also lessened the
• 43:21
  abnormal subchondral bone changes that typically
• 43:24
  occur after such an injury. That's quite compelling
• 43:26
  evidence for the potential benefit of very early
• 43:28
  intervention. That preclinical finding really
• 43:30
  is compelling. What about bone marrow aspirate
• 43:33
  concentrate, BMAC? That's another cell -based
• 43:35
  approach using the patient's own tissue. Yes,
• 43:38
  BMAC is produced by taking bone marrow, usually
• 43:40
  from the hip bone, and then concentrating it.
• 43:43
  typically using a centrifuge. What's in it? It
• 43:45
  contains a mixed population of cells naturally
• 43:47
  present in bone marrow platelets, various types
• 43:50
  of immune cells, lymphocytes, monocytes, granulocytes,
• 43:53
  progenitor cells, and importantly a small proportion
• 43:56
  of MSCs and hematopoietic stem cells, HSCs. The
• 44:00
  concentration process typically increases the
• 44:01
  total number of nucleated cells several fold
• 44:04
  compared to the original bone marrow aspirate.
• 44:06
  And how is it being used for early OA? The Mbrede
• 44:09
  has shown some promise in studies for treating
• 44:11
  early OA and is generally considered safe as
• 44:14
  it's using the patient's own cells with minimal
• 44:16
  manipulation. Studies do report reductions in
• 44:19
  pain and improvements in joint function after
• 44:21
  BMAC injections. But are there limitations? Yes,
• 44:25
  the sources highlight some major limitations.
• 44:27
  Firstly, whether BMA truly leads to tissue regeneration
• 44:30
  is still unresolved. Secondly, the results reported
• 44:33
  in studies vary quite widely in terms of efficacy.
• 44:35
  Why the variability? It likely points to a real
• 44:38
  need for standardization in how the BMA is processed,
• 44:42
  which technique is used, and importantly, the
• 44:45
  final dosage or cell concentration injected.
• 44:48
  A big challenge is that many published clinical
• 44:50
  studies unfortunately don't report the specific
• 44:52
  cellular composition or concentration of the
• 44:55
  BMAC product they used. Making it hard to compare
• 44:58
  studies or know it actually works? Exactly. It
• 45:01
  makes it almost impossible to compare results
• 45:03
  properly or to figure out what might be a minimum
• 45:05
  effective dose or the optimal composition. And
• 45:08
  as with MSCs, longer -term follow -up studies
• 45:11
  are definitely needed to understand the exact
• 45:13
  effects of BMAs on disease progression over many
• 45:16
  years. So again, potential, but still a lot of
• 45:19
  unknowns, and a need for more rigorous, standardized
• 45:21
  research. What about using fat cells more directly,
• 45:24
  perhaps without expanding them in a lab first?
• 45:27
  The sources briefly touch on these less -processed,
• 45:29
  adipose -derived cell preparations. Things like
• 45:32
  stromal vascular fraction, or SVF, which is a
• 45:34
  mix of cells isolated from fat tissue, or microfragmented
• 45:38
  adipose tissue, sometimes called new fat or lipogems.
• 45:41
  Any evidence for these? Research, particularly
• 45:43
  some promising animal studies. for example, in
• 45:46
  dogs with OA, shows potential benefits. One study
• 45:50
  cited using microfragmented adipose tissue reported
• 45:53
  improvements in function, reduced pain, and fewer
• 45:56
  symptoms lasting for at least six months after
• 45:58
  injection. How are they thought to work? The
• 46:01
  suggested mechanism, again, seems to be primarily
• 46:03
  via paracrine effects, analgesic pain relieving,
• 46:07
  anti -inflammatory, and trophic. providing nourishing
• 46:10
  factors, activities from the cells within the
• 46:12
  fat tissue. The resulting repair tissue observed
• 46:15
  wasn't typically normal hyaline cartilage. again
• 46:18
  suggesting the action is mainly through signaling
• 46:20
  rather than the fat cells directly turning into
• 46:22
  cartilage. Okay. Another cutting -edge area mentioned
• 46:24
  is using just the signals themselves, MSC -derived
• 46:28
  extracellular vesicles or EVs. Yes, this is an
• 46:31
  exciting but very early stage field. EVs, particularly
• 46:34
  exosomes, are those tiny packages released by
• 46:37
  MSCs that carry many of the signaling molecules
• 46:40
  responsible for the therapeutic paracoin effects.
• 46:42
  So the idea is to deliver just the message, not
• 46:44
  the whole cell. Exactly. to harness the therapeutic
• 46:47
  potential without needing to inject living cells,
• 46:50
  which might overcome some challenges related
• 46:52
  to cell survival, sourcing, and consistency.
• 46:56
  But there are challenges with EVs, too. Significant
• 46:58
  challenges, yes. The sources point out that characterization
• 47:02
  is difficult. While there are some general pan
• 47:04
  -EV markers, like CD9 or CD63, there isn't a
• 47:08
  single unique marker to identify specific therapeutic
• 47:11
  EVs. And distinguishing potentially helpful EVs
• 47:14
  from other micro - vesicles or cellular debris
• 47:17
  is complex. And getting them to the right place.
• 47:20
  Biodistribution is another issue. Once injected
• 47:22
  into the joint, where do they go? How long do
• 47:24
  they stick around? Their fate is largely unknown,
• 47:26
  and there's potential for them to be cleared
• 47:28
  quite rapidly from the joint space, limiting
• 47:30
  their effect. So lots of potential, but many
• 47:33
  hurdles to overcome before EV therapy becomes
• 47:36
  a clinical reality. And looking even further
• 47:38
  ahead, perhaps, induced pluripotent stem cells,
• 47:41
  IPS cells. IPS cells represent another frontier.
• 47:45
  These are adult cells, like skin or blood cells,
• 47:48
  that have been reprogrammed in the lab back to
• 47:51
  a very early embryonic -like pluripotent state,
• 47:55
  meaning they can potentially develop into any
• 47:56
  cell type in the body. How might they be used
• 47:59
  for cartilage repair? The hope is that because
• 48:02
  they start from such an early stage, they could
• 48:04
  be directed to differentiate into chondrocytes
• 48:07
  that might integrate more effectively into the
• 48:09
  native cartilage defect, potentially mimicking
• 48:12
  normal cartilage development better than cells
• 48:15
  derived from more mature sources. Is this being
• 48:17
  tested? Research is still in the early phases.
• 48:20
  The source has mentioned studies exploring different
• 48:21
  protocols to guide iPS cells towards becoming
• 48:24
  cartilage cells using specific growth factors,
• 48:27
  co -culture systems, etc. There's debate about
• 48:29
  the best initial cell source for reprogramming
• 48:32
  peripheral blood or umbilical cord blood are
• 48:34
  mentioned as being easily accessible. What about
• 48:36
  safety? Is there a risk of tumors with pluripotent
• 48:39
  cells? That's always a key concern with pluripotent
• 48:42
  cells. However, the sources specifically note
• 48:45
  that the studies mentioned did not report any
• 48:48
  teratoma or tumor formation, which is obviously
• 48:50
  crucial for safety. But it's still a long way
• 48:53
  off clinical use. Very much so. The sources suggest
• 48:57
  that while certain lab protocols look promising
• 48:59
  pre -clinically, much more in vivo work in animal
• 49:02
  models and eventually rigorous clinical trials
• 49:04
  are needed before iPS cell -based therapies could
• 49:07
  even be considered for treating OA in patients.
• 49:10
  Okay, that's a fascinating overview of the non
• 49:13
  -surgical and biological approaches from established
• 49:16
  treatments to the very cutting edge. The sources
• 49:18
  also detail various surgical interventions, particularly
• 49:22
  relevant for focal cartilage defects, or perhaps
• 49:25
  more advanced issues, even in younger people
• 49:27
  sometimes. Let's start with cartilage restoration
• 49:30
  techniques for those localized defects. Microfracture
• 49:32
  is a common one. Yes, microfracture is a well
• 49:35
  -established technique. It involves creating
• 49:37
  small perforations, essentially drilling tiny
• 49:39
  holes through the base of the cartilage defect
• 49:41
  into the underlying subcontral bone. Why drill
• 49:44
  into the bone? The idea is to allow blood and
• 49:47
  bone marrow elements, including progenitor cells,
• 49:49
  potentially some MSCs, and growth factors to
• 49:52
  seep into the defect and stimulate a healing
• 49:54
  response. What kind of tissue forms? It typically
• 49:57
  results in the formation of fibrocartilage repair
• 50:00
  tissue. This isn't the same as the original hyaline
• 50:03
  cartilage. It's mechanically inferior, more like
• 50:05
  scar tissue, mainly composed of tight eye collagen
• 50:08
  instead of the normal type 2. But it does help
• 50:12
  to fill the defect. provides some covering for
• 50:14
  the bone, and the theory is it might protect
• 50:16
  the surrounding healthy cartilage from further
• 50:19
  damage or overload. Is it used for early OA?
• 50:22
  It's primarily established for treating smaller
• 50:24
  contained focal cartilage defects, particularly
• 50:27
  in younger active patients. It has been investigated
• 50:29
  for early OA, perhaps where there's a significant
• 50:32
  focal lesion driving symptoms, and reasonable
• 50:35
  midterm outcomes have been reported. What about
• 50:37
  techniques that aim for better quality repair
• 50:39
  tissue, more like the original hyaline cartilage?
• 50:42
  That's where techniques like autologous chondrocyte
• 50:44
  implantation, ACI, or its more modern matrix
• 50:48
  -assisted version, MACI, come in. This is usually
• 50:51
  a two -stage procedure. Two stages. Yes. In the
• 50:54
  first surgery, a small biopsy of healthy cartilage
• 50:58
  is taken from a less critical area of the patient's
• 51:00
  own knee. The chondrocytes from this biopsy are
• 51:03
  then isolated and grown, expanded in number,
• 51:06
  in a laboratory over several weeks. And the second
• 51:09
  stage? In the second surgery, these cultured
• 51:11
  chondrocytes are implanted back into the cartilage
• 51:14
  defect. In ACI, they're typically seated onto
• 51:17
  a biological scaffold or membrane, which is then
• 51:20
  secured into the defect, often covered with a
• 51:22
  patch. And this produces better cartilage. The
• 51:24
  goal, and often the result, is the formation
• 51:26
  of hyaline -like cartilage, which is biomechanically
• 51:29
  superior to the fibrocartilage from microfracture.
• 51:33
  Asimisi is generally used for larger defects,
• 51:35
  say over 2 to 4 square centimeters, and particularly
• 51:38
  in certain locations like the patellofemoral
• 51:40
  joint behind the kneecap. Long -term patient
• 51:43
  satisfaction rates are generally reported as
• 51:44
  being quite high. What are the downsides? Well,
• 51:47
  it's two surgeries, which means more recovery
• 51:49
  time and cost. And a major challenge highlighted
• 51:52
  in the sources is the very intensive and prolonged
• 51:55
  rehabilitation required afterwards. Getting quadriceps
• 51:58
  muscle strength back in particular can be a real
• 52:00
  struggle and can take up to a year or even longer.
• 52:03
  New rehab strategies like high -intensity training
• 52:06
  or blood flow restriction therapy are being explored
• 52:09
  to try and address this muscle weakness issue.
• 52:11
  Like microfracture, ACI is also being investigated
• 52:14
  for its potential role in treating specific situations
• 52:17
  in early OA. OK. What about using donor tissue
• 52:21
  instead, osteochondral allograft transplantation?
• 52:24
  Yes, an osteochondral allograft involves transplanting
• 52:27
  a cylinder or block of mature high -lying cartilage
• 52:29
  still attached to its underlying bone taken from
• 52:32
  a deceased donor. What are the advantages of
• 52:34
  using donor tissue? Several key advantages. Firstly,
• 52:37
  it's usually a single stage procedure, unlike
• 52:39
  ACI. Secondly, it immediately fills the defect
• 52:43
  with mature, structurally sound tissue. Thirdly,
• 52:47
  there's no need to harvest tissue from the patient's
• 52:49
  own healthy joint, avoiding donor site morbidity.
• 52:52
  It's also very versatile. It can be used for
• 52:54
  defects of almost any size, including very large
• 52:57
  or complex ones. And it's particularly useful
• 52:59
  for situations involving bone loss or abnormalities
• 53:02
  in the subchondral bone or complex shapes like
• 53:06
  on the patella. Any other benefits? A really
• 53:08
  interesting point made in the sources is that
• 53:10
  it's effectively a denervating technique. Because
• 53:13
  you're replacing the damaged, potentially painful
• 53:16
  subchondral bone along with the cartilage, patients
• 53:19
  often experience immediate pain relief from the
• 53:21
  procedure itself, which can be quite dramatic
• 53:23
  compared to techniques that rely on stimulating
• 53:26
  biological repair over time. That's significant.
• 53:28
  Is it used for early OA? It's being investigated
• 53:31
  for both early OA, especially with larger or
• 53:33
  deeper lesions, and for complex chondral problems
• 53:36
  that might not be suitable for other techniques.
• 53:39
  Research looking at the outcomes using refrigerated
• 53:41
  fresh allografts is mentioned. So a range of
• 53:43
  options for fixing localized cartilage damage,
• 53:46
  each with its own pros, cons, and indications.
• 53:49
  The sources also cover osteotomy procedures bone
• 53:52
  realignment surgery. Yes, high tibial osteotomy
• 53:55
  or HTO is specifically mentioned. This is a procedure
• 53:59
  typically used to correct bow -legged alignment
• 54:01
  or virus deformity in the knee. How does it help
• 54:04
  OA? By cutting and carefully realigning the upper
• 54:06
  part of the tibia, shin bone, it shifts the main
• 54:09
  weight -bearing axis of the leg away from the
• 54:11
  damaged intermedial compartment of the knee onto
• 54:13
  the healthier outer lateral compartment. This
• 54:16
  offloads the worn area, reducing pain and potentially
• 54:19
  slowing further degeneration. Is it done alongside
• 54:22
  cartilage repair? Often, yes. HDO can be combined
• 54:25
  with cartilage restoration procedures like microfracture,
• 54:28
  ACI, or allograft transplantation if there is
• 54:31
  a significant cartilage defect in the overloaded
• 54:34
  compartment. Studies looking at these combined
• 54:36
  procedures generally report reliable improvements
• 54:39
  in function over the medium to long term. One
• 54:42
  systematic review site had found favorable results,
• 54:45
  although conversion to a total knee replacement
• 54:47
  was still necessary in a small percentage of
• 54:49
  patients down the line, around 7 % at about six
• 54:52
  years follow -up in that review. So it can delay
• 54:55
  or avoid knee replacement for some? That's the
• 54:57
  goal, particularly in younger, more active patients
• 55:00
  with unicompartmental OA and malalignment. The
• 55:03
  sources correctly point out though that more
• 55:05
  studies with control groups are needed to really
• 55:07
  understand the added benefit of performing cartilage
• 55:09
  restoration at the same time as the osteotomy
• 55:12
  versus doing the osteotomy alone. They also briefly
• 55:15
  mentioned the potential for subchondral drilling
• 55:17
  or other techniques to possibly stimulate cartilage
• 55:20
  regeneration after the opposite type of osteotomy,
• 55:23
  valgus osteotomy for knock knees. Okay, let's
• 55:25
  switch joints now and move to the shoulder. The
• 55:28
  sources discuss shoulder arthroplasty shoulder
• 55:31
  replacement surgery. This seems more for advanced
• 55:34
  OA, but perhaps considered in younger patients
• 55:36
  too. Yes, the management pathway for shoulder
• 55:38
  arthritis mirrors the knee in many ways, starting
• 55:41
  with non -surgical options like physio, medication,
• 55:44
  injections. But surgery often becomes necessary
• 55:46
  for significant pain and loss of function. The
• 55:49
  source is specifically defined dislocation arthropathy
• 55:52
  as arthritis that develops as a consequence of
• 55:55
  previous shoulder instability, highlighting again
• 55:58
  how mechanical factors like recurrent dislocations
• 56:01
  can directly lead to cartilage breakdown and
• 56:04
  OA in the shoulder joint. For younger, more active
• 56:06
  patients needing surgery is total shoulder arthroplasty,
• 56:10
  TSA replacing both the ball and the socket, generally
• 56:12
  preferred for the best function. Often, yes.
• 56:15
  TSA is frequently the preferred option for primary
• 56:18
  Glenohumeral OA, arthritis of the main ball and
• 56:21
  socket joint, and active higher demand patients,
• 56:24
  provided their rotator cuff tendons are either
• 56:26
  intact or can be reliably repaired at the same
• 56:29
  time. When successful, TSA can offer significant
• 56:32
  improvements in both pain relief and range of
• 56:35
  emotion. But there are risks. A major risk highlighted
• 56:37
  is instability, especially if there are medium
• 56:40
  or large rotator cuff tears present. The sources
• 56:43
  state that about half of patients who have significant
• 56:45
  vocator cuff tears managed alongside a TSA end
• 56:48
  up needing revision surgery. There's also a trend
• 56:51
  mentioned towards performing TSA as an outpatient
• 56:54
  procedure in carefully selected younger patients,
• 56:57
  potentially saving costs. But patient selection
• 56:59
  based on age, BMI, other health conditions, and
• 57:02
  crucially, having good support at home is absolutely
• 57:04
  critical for safety and success. A big question
• 57:06
  for younger patients must be, how long do these
• 57:09
  shoulder replacements actually last, especially
• 57:12
  if they're active? That is indeed the challenge.
• 57:14
  While TSA generally offers the best functional
• 57:17
  outcomes, the potential for the implant components,
• 57:21
  particularly the plastic socket, glenoid, to
• 57:23
  wear out or loosen over time is a real consideration,
• 57:26
  and this risk is likely higher in more active
• 57:29
  individuals who place greater demands on the
• 57:31
  joint. One study cited found a survivorship rate
• 57:34
  of the implant of around 62 .5 % at 10 -year
• 57:37
  follow -up for patients under the age of 55.
• 57:40
  So nearly 40 % needed revision within 10 years
• 57:43
  in that group. In that particular study, yes.
• 57:46
  It indicates that while TSA can be very effective,
• 57:49
  the need for revision surgery within a decade
• 57:51
  or two is a distinct possibility for younger
• 57:54
  active patients, and that needs to be part of
• 57:56
  the conversation. And return to work or sport
• 57:59
  must be a huge factor for this demographic. Absolutely
• 58:01
  crucial. It's often a primary goal. The sources
• 58:04
  say the meta -analysis looking at return to play
• 58:06
  after different types of shoulder replacement.
• 58:08
  It showed higher rates after TSA. Over 90 % were
• 58:11
  able to return to some form of sport. That's
• 58:12
  high. Compared to reverse shoulder arthroplasty,
• 58:15
  RSA, or hemiarthroplasty, just replacing the
• 58:18
  ball, which were both around 70%. And importantly
• 58:22
  nearly 80 % of those returning after TSA were
• 58:25
  able to get back to the same level of play they
• 58:27
  enjoyed before their shoulder problems became
• 58:29
  severe. Any specific examples? High return rates
• 58:32
  to sports like golf after TSA are given as an
• 58:35
  example, often 90 -100%, with lower rates typically
• 58:39
  seen after RSA or hemiarthroplasty. However,
• 58:42
  a key point emphasized is that there are currently
• 58:44
  no clear evidence -based guidelines on exactly
• 58:47
  how long patients should wait before returning
• 58:49
  to demanding activities or sports. This needs
• 58:52
  to be highly individualized, based on their progress
• 58:54
  with regaining stability, strength, range of
• 58:57
  motion, and proprioception, their sense of joint
• 58:59
  position. The sources also get into some of the
• 59:01
  specific technical challenges surgeons face,
• 59:03
  like dealing with bone loss on the socket side,
• 59:05
  the glenoid. Yes. They discuss the Walsh classification
• 59:08
  system, which categorizes patterns of glenoid
• 59:11
  wear and bone loss in OA. They note that certain
• 59:14
  patterns, particularly those with significant
• 59:16
  bone erosion on the back of the socket, type
• 59:18
  E glenoids, are associated with higher rates
• 59:21
  of complications and the need for revision surgery
• 59:23
  after TSA. How do surgeons address that bone
• 59:27
  loss? Various strategies are used. For smaller
• 59:30
  defects, sometimes asymmetric reaming selectively
• 59:33
  shaping the remaining bone can work. For larger
• 59:36
  defects, bone grafting or using specialized augmented
• 59:39
  glenoid components with built -in wedges or steps
• 59:41
  might be necessary to restore the joint line
• 59:44
  and ensure stable fixation. However, the sources
• 59:47
  note that the results with some of these specialized
• 59:49
  augmented components are only moderate, with
• 59:51
  variable reports of loosening or revision rates.
• 59:54
  Okay. What about in reverse shoulder arthroplasty
• 59:56
  RSA? That's used more when the rotator cuff is
• 59:59
  badly damaged, right? Is stability a concern
• 1:00:01
  there, too? Yes. RSA is typically used when the
• 1:00:04
  rotator cuff is deficient and can't be repaired,
• 1:00:07
  as it relies more on the deltoid muscle for function.
• 1:00:10
  Stability is still critical. The sources discuss
• 1:00:13
  design features and surgical techniques aimed
• 1:00:16
  at enhancing stability in RSA, such as using
• 1:00:19
  an inferior eccentric glenosphere that's the
• 1:00:21
  ball component placed on the socket side in an
• 1:00:23
  RSA. Placing it slightly off -center and low
• 1:00:26
  helps prevent impingement or notching, where
• 1:00:29
  the arm bone implant rubs against the scapula,
• 1:00:32
  and it also improves stability by increasing
• 1:00:34
  the compressive forces across the joint. Placing
• 1:00:37
  the base plate component as low as possible on
• 1:00:39
  the glenoid is also recommended for stability.
• 1:00:42
  Any other techniques? Biomechanical studies cited
• 1:00:44
  suggest that tilting the glenoid component slightly
• 1:00:46
  downwards, about 15 degrees, also maximizes these
• 1:00:50
  compressive forces and reduces the risk of dislocation.
• 1:00:53
  They also touch on the role of the subscapularis
• 1:00:54
  muscle. The one at the front? Yes. The subscapularis
• 1:00:57
  is vital for preventing anterior dislocation
• 1:01:00
  after a standard TSA. Its role in RSA might be
• 1:01:04
  less critical, especially with certain lateralized
• 1:01:06
  RSA designs where the deltoid muscle provides
• 1:01:09
  more inherent compression, but it's still often
• 1:01:12
  repaired if possible. Speaking of the subscapularis,
• 1:01:15
  managing it during the surgical approach for
• 1:01:16
  a standard TSA seems really important for the
• 1:01:19
  outcome. It's absolutely critical for the stability
• 1:01:21
  and function of the final replacement. The sources
• 1:01:23
  discuss the different ways surgeons can handle
• 1:01:25
  the subscapularis tendon to get access to the
• 1:01:28
  joint. Sometimes it's cut transversely, tenotomy.
• 1:01:31
  Sometimes peeled off the bone, peel. Or sometimes
• 1:01:34
  a piece of the bone where it attaches is cut
• 1:01:35
  and later repaired. Lesser tuberosity, osteotomy,
• 1:01:38
  or LTO. Is one method better? Some biomechanical
• 1:01:42
  studies suggest the LTO might provide the best
• 1:01:44
  strength and stability after repair, although
• 1:01:46
  this isn't universally agreed upon. And healing
• 1:01:49
  can sometimes be an issue. What is crucial? regardless
• 1:01:52
  of the method used, is achieving a strong, reliable
• 1:01:56
  primary repair of the tendon or bone fragment
• 1:01:59
  at the end of the surgery. Failure of this subscapularis
• 1:02:02
  repair is a common reason for pain, weakness,
• 1:02:06
  instability, and potentially needing re -operation.
• 1:02:08
  Are there ways to avoid cutting it at all? The
• 1:02:10
  sources also mention a subscapularis sparing
• 1:02:13
  surgical approach. The idea here is to work around
• 1:02:15
  the main tendon, often by splitting fibers rather
• 1:02:18
  than detaching it completely. This potentially
• 1:02:21
  avoids the problems associated with repair failure
• 1:02:23
  and tendon degeneration and might allow for faster
• 1:02:26
  rehabilitation by preserving the upper, most
• 1:02:29
  functionally important portion of the muscle.
• 1:02:31
  Interesting. Beyond instability and managing
• 1:02:33
  the surgical approach, what are the other common
• 1:02:35
  complications discussed for shoulder replacement?
• 1:02:37
  A septic glenoid loosening, meaning the socket
• 1:02:40
  component coming loose without any infection
• 1:02:42
  being present, is highlighted as the most common
• 1:02:45
  reason for needing revision surgery after an
• 1:02:47
  anatomic TSA. Why does it loosen? It's often
• 1:02:50
  attributed to repetitive, uneven forces across
• 1:02:53
  the joint, causing micro -motion at the implant
• 1:02:55
  bone interface, leading to wear debris and eventually
• 1:02:58
  loosening. This is sometimes called the rocking
• 1:03:00
  horse phenomenon. Seeing radiolucent lines, or
• 1:03:03
  gaps, around cemented implants on x -rays can
• 1:03:06
  be an early sign, although using newer, more
• 1:03:09
  wear -resistant plastics like highly cross -linked
• 1:03:11
  polyethylene, XLPE, seems to reduce this risk.
• 1:03:15
  The debate between different socket fixation
• 1:03:17
  designs, keeled versus pegged, is mentioned,
• 1:03:20
  with large registry data suggesting similar revision
• 1:03:22
  rates nowadays, likely due to modern cementing
• 1:03:25
  techniques and better materials. Loosening is
• 1:03:28
  influenced by many factors. The patient's bone
• 1:03:30
  quality, the surgeon's accuracy in positioning
• 1:03:33
  the component, the implant design itself, and
• 1:03:35
  the forces the patient puts across the joint.
• 1:03:38
  Infection is always a risk with joint replacement
• 1:03:40
  too, right? Paraprosthetic joint infection, PJI.
• 1:03:43
  Yes. PJI is another serious complication, and
• 1:03:46
  it's critical to diagnose it accurately if a
• 1:03:48
  shoulder replacement isn't performing well. The
• 1:03:51
  sources refer to established diagnostic guidelines,
• 1:03:54
  like the International Consensus Meeting. ICM
• 1:03:57
  2018 criteria for shoulder PGI, which use a combination
• 1:04:00
  of major criteria like seeing pus or having multiple
• 1:04:04
  positive cultures and minor criteria like elevated
• 1:04:08
  inflammatory markers in blood or joint fluid
• 1:04:10
  to classify the likelihood of infection. How
• 1:04:12
  is it treated? Treatment is challenging. Antibiotics
• 1:04:15
  alone are usually insufficient because bacteria
• 1:04:18
  can form protective biofilms on the implant surface.
• 1:04:21
  Trying to keep the implant while just cleaning
• 1:04:23
  out the infection surgically, debridement and
• 1:04:25
  retention is debated with limited strong evidence
• 1:04:27
  supporting it routinely although it might be
• 1:04:30
  considered in very specific acute situations.
• 1:04:33
  Often more complex revision surgery involving
• 1:04:35
  implant removal is needed. Fractures around the
• 1:04:37
  implant are also mentioned. Yes. Paraprosthetic
• 1:04:40
  humerus fractures breaks in the upper arm bone
• 1:04:43
  around the stem of the implant or a known complication.
• 1:04:46
  Classifications exist to help surgeons decide
• 1:04:48
  on treatment. Fractures where the implant itself
• 1:04:51
  has become unstable typically require complex
• 1:04:54
  revision surgery to fix both the fracture and
• 1:04:57
  stabilize or replace the implant. Prevention
• 1:04:59
  is key here, emphasizing careful preoperative
• 1:05:02
  planning to choose the right implant size and
• 1:05:05
  meticulous surgical technique, especially during
• 1:05:08
  revision surgeries, to avoid weakening or damaging
• 1:05:10
  the bone. Even after a fracture heals surgically,
• 1:05:14
  patients often have some lasting functional limitations,
• 1:05:17
  particularly with range of motion. Finally, the
• 1:05:19
  source is briefly mentioned using arthroscopy
• 1:05:21
  keyhole surgery after a shoulder replacement
• 1:05:23
  has already been done. Is there a role for that?
• 1:05:26
  Potentially. Yes, in very selective circumstances.
• 1:05:29
  Arthroscopy might have a limited role in managing
• 1:05:31
  certain issues after arthroplasty, like persistent
• 1:05:34
  pain, stiffness, or limited movement that hasn't
• 1:05:36
  responded to rehabilitation, provided that infection
• 1:05:39
  and problems with the implant components themselves,
• 1:05:41
  like loosening or instability, have been confidently
• 1:05:44
  ruled out. What can be done arthroscopically?
• 1:05:47
  Procedures like releasing scar tissue, capsular
• 1:05:50
  release, Or removing adhesions, lysis of adhesions,
• 1:05:54
  can sometimes be performed using keyhole techniques.
• 1:05:57
  Studies looking at this are limited, but successful
• 1:05:59
  outcomes have been reported in carefully chosen
• 1:06:01
  patients where the underlying problem is soft
• 1:06:04
  tissue restriction rather than an implant issue.
• 1:06:07
  And one last thing on surgery. How is technology
• 1:06:10
  like computer navigation or patient -specific
• 1:06:13
  guides changing shoulder replacement? These technologies,
• 1:06:16
  things like preoperative planning software using
• 1:06:19
  CT scans, 3D printed patient -specific instrument
• 1:06:21
  guides, BSI, and real -time computer navigation
• 1:06:24
  systems used during surgery are definitely being
• 1:06:26
  adopted to try and improve the accuracy of place
• 1:06:29
  of the components, particularly the glenoid socket
• 1:06:31
  in both TSA and RSA. They help surgeons achieve
• 1:06:34
  the planned orientation and position more reliably.
• 1:06:37
  Does better accuracy mean better results for
• 1:06:39
  patients? Well, that's the crucial question.
• 1:06:41
  And the sources point out that there is currently
• 1:06:43
  little direct evidence to definitively prove
• 1:06:46
  that this increased surgical accuracy actually
• 1:06:49
  translates into improved long -term implant survival
• 1:06:52
  rates or better functional outcomes for patients.
• 1:06:55
  It makes intuitive sense that it should, but
• 1:06:57
  the high -level evidence isn't quite there yet.
• 1:06:59
  Interesting. Are there limitations to the current
• 1:07:02
  planning tech? They also note a limitation in
• 1:07:05
  most current planning software. It mainly focuses
• 1:07:08
  on the relationship between the ball and socket
• 1:07:10
  implants themselves. But the shoulder's actual
• 1:07:13
  functional motion is complex and heavily influenced
• 1:07:15
  by the movement of the shoulder blade on the
• 1:07:17
  rib cage, scapula thoracic motion, and other
• 1:07:20
  factors outside the joint, like posture or spinal
• 1:07:22
  curves. Ideally, future planning tools need to
• 1:07:25
  incorporate these broader factors for truly comprehensive,
• 1:07:28
  patient -specific surgical planning. That's been
• 1:07:30
  a really comprehensive deep dive into the whole
• 1:07:33
  landscape of early OA. We've gone from its subtle
• 1:07:36
  beginnings in complex biology right through to
• 1:07:39
  its significant personal and economic impact
• 1:07:42
  and the wide range of current and future treatment
• 1:07:44
  approaches. As we start to wrap up, let's just
• 1:07:47
  summarize some of the big challenges and perhaps
• 1:07:49
  the most promising areas for the future that
• 1:07:51
  emerged from these sources. Well, the challenges
• 1:07:53
  are certainly significant, aren't they? Diagnosing
• 1:07:56
  early OA reliably is still tough because it's
• 1:07:59
  often or symptoms are nonspecific. The underlying
• 1:08:03
  pathology is clearly a complex mix of inflammation,
• 1:08:07
  altered mechanics, and cellular dysfunction.
• 1:08:09
  Treatment outcomes are still quite variable,
• 1:08:12
  and there's a real urgent need for standardization,
• 1:08:14
  particularly for the newer biologic therapies
• 1:08:16
  like MSCs or BMAs, so we can actually compare
• 1:08:19
  results properly. And of course, surgical options,
• 1:08:22
  while powerful, come with inherent risks, limitations,
• 1:08:26
  and the particular challenge of achieving long
• 1:08:28
  -term durability in younger, more active patients.
• 1:08:30
  But despite all those challenges, the research
• 1:08:32
  definitely offers some promising directions forward,
• 1:08:35
  doesn't it? Absolutely. The potential of biologics,
• 1:08:38
  particularly MSCs and perhaps eventually their
• 1:08:40
  EVs, to truly modify the disease process rather
• 1:08:44
  than just treating symptoms is incredibly exciting,
• 1:08:47
  although much more rigorous research and well
• 1:08:49
  -controlled clinical translation are clearly
• 1:08:51
  needed. What else looks promising? Ongoing work
• 1:08:54
  that continues to clarify the specific inflammatory
• 1:08:57
  pathways involved and understanding the precise
• 1:09:00
  effects of different types and intensities of
• 1:09:02
  mechanical loading on joint tissues. These offer
• 1:09:05
  potential targets for new drug developments or,
• 1:09:08
  perhaps more immediately, more refined and biologically
• 1:09:11
  informed rehabilitation strategies. Improved
• 1:09:13
  surgical techniques, materials, and planning
• 1:09:15
  tools also continue to evolve, always aiming
• 1:09:18
  for better longevity and function. And although
• 1:09:20
  it's still in very early stages, the gene therapy
• 1:09:23
  research mentioned, aiming to perhaps deliver
• 1:09:25
  therapeutic molecules like IL -1 inhibitors directly
• 1:09:28
  and sustainably within the joint, represents
• 1:09:30
  another potential long -term avenue. So lots
• 1:09:33
  happening at the research level. Yes. But the
• 1:09:36
  crucial next step, as always, is translating
• 1:09:38
  all this promising basic science and preclinical
• 1:09:41
  work into practical, effective, and accessible
• 1:09:44
  treatments for patients. And that requires developing
• 1:09:47
  better tools to identify at -risk individuals
• 1:09:49
  early, refining our outcome measures, and running
• 1:09:52
  large, well -designed, long -term clinical trials.
• 1:09:55
  And finally, just bringing it back to you, the
• 1:09:57
  listener, navigating your professional life.
• 1:09:59
  How does understanding this really nuanced, detailed
• 1:10:03
  picture of early OA, science, the impact, the
• 1:10:06
  treatments, how does that tie back to your world?
• 1:10:08
  I think it's fundamental really. Understanding
• 1:10:10
  the why behind early OA, why injuries pose such
• 1:10:14
  a significant risk, why it's fundamentally an
• 1:10:16
  inflammatory process, understanding the true
• 1:10:18
  scale of the economic cost it equips you to make
• 1:10:21
  much more informed decisions, both personally
• 1:10:23
  and professionally. In what way? It's about recognizing
• 1:10:25
  potential personal risk. Perhaps if you or colleagues
• 1:10:28
  are very active or have sustained significant
• 1:10:30
  joint injuries in the past. It's about understanding
• 1:10:33
  the potential long -term implications for career
• 1:10:35
  longevity if OA develops early. It helps appreciate
• 1:10:39
  the critical need for effective early intervention
• 1:10:41
  and properly guided rehabilitation strategies,
• 1:10:43
  not just letting things slide. And it allows
• 1:10:46
  seeing the broader picture of how this condition
• 1:10:48
  impacts workforce productivity and health care
• 1:10:50
  resources. It reframes early OA not just as some
• 1:10:54
  distant health problem you might face in old
• 1:10:55
  age, but as a relevant professional and societal
• 1:10:58
  challenge that requires proactive awareness and
• 1:11:01
  engagement right now. That connection is powerful,
• 1:11:03
  thinking of it not just as a joint issue, but
• 1:11:05
  potentially a workforce issue. So to quickly
• 1:11:08
  recap just a few key insights from this deep
• 1:11:11
  dive, early OA is often a subtle, frequently
• 1:11:13
  injury -driven condition that's increasingly
• 1:11:15
  affecting younger, active individuals. Its underlying
• 1:11:19
  pathology is a complex interplay of inflammation
• 1:11:22
  and mechanics, challenging the old wear and pair
• 1:11:24
  notion. And it imposes a huge economic burden
• 1:11:27
  through lost productivity and health care costs.
• 1:11:31
  diagnosis and treatment remain challenging and
• 1:11:33
  are constantly evolving, promising new biological
• 1:11:36
  approaches like cell therapies alongside refined
• 1:11:39
  surgical techniques, offer hope for the future,
• 1:11:42
  but emphasize the critical need for continued
• 1:11:44
  research and standardization. A truly dynamic
• 1:11:47
  and challenging field indeed. So given the strong
• 1:11:50
  evidence we've discussed today, linking specific
• 1:11:52
  mechanical load profiles directly to those inflammatory
• 1:11:55
  pathways within the joint, here's perhaps a provocative
• 1:11:58
  thought to mull over. How can we fundamentally
• 1:12:01
  reinvent rehabilitation and training programs,
• 1:12:04
  not just to restore strength or function, but
• 1:12:07
  to actively manage and perhaps even interrupt
• 1:12:09
  the underlying biological progression of post
• 1:12:12
  -traumatic osteoarthritis in those high -demand
• 1:12:14
  individuals? That's a key question, isn't it?
• 1:12:16
  Moving rehab beyond mechanics into biology. It
• 1:12:19
  could have... potentially transformative implications.
• 1:12:22
  If you found this deep dive helpful and informative,
• 1:12:25
  please do take a moment to rate and share the
• 1:12:27
  show with your colleagues and professional network.
• 1:12:29
  It really helps us bring you more of the in -depth
• 1:12:31
  analysis you need to stay informed on critical
• 1:12:34
  topics like this.